Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,293 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients | recruiting | Phase 3 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04702581 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery(POLO) | recruiting | Phase 3 | 280 | Hospices Civils de LyonOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT06105619 | A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | active not recruiting | Phase 2 / Phase 3 | 84 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma | not yet recruiting | Phase 3 | 96 | Nationwide Children's HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme(INTRAGO-II) | active not recruiting | Phase 3 | 314 | Universitätsmedizin MannheimOTHER | 8 | Oct 14, 2025 | clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT02864888 | Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma(DBSG) | not yet recruiting | Phase 3 | 30 | Burzynski Research InstituteOTHER | 0 | Sep 19, 2025 | clinicaltrials |
| NCT02887040 | Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma(DIPG) | not yet recruiting | Phase 3 | 92 | Burzynski Research InstituteOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT01351870 | Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)(SIOP-PNET-4) | completed | Phase 3 | 52 | Institut CurieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | terminated | Phase 3 | 2 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT07004075 | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration | not yet recruiting | Phase 3 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05439278 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | recruiting | Phase 3 | 178 | Severance HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06750458 | Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | not yet recruiting | Phase 3 | 75 | Tanta UniversityOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT03632135 | Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma(CSCRGBM) | completed | Phase 3 | 78 | Cordgenics, LLCINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02017717 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients(CheckMate 143) | completed | Phase 3 | 529 | Bristol-Myers SquibbINDUSTRY | 12 | Apr 4, 2025 | clinicaltrials |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | active not recruiting | Phase 3 | 331 | Institut de Recherches Internationales ServierOTHER | 11 | Apr 3, 2025 | clinicaltrials |
| NCT06749925 | Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma | not yet recruiting | Phase 3 | 186 | University of Sao Paulo General HospitalOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05512403 | Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics(KING) | recruiting | Phase 3 | 88 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00653068 | Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System | completed | Phase 3 | 70 | Children's Oncology GroupNETWORK | 3 | Apr 23, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | suspended | Phase 3 | 234 | Precision Life Sciences GroupINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06330337 | Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma | recruiting | Phase 3 | 58 | The Third Affiliated hospital of Zhejiang Chinese Medical UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT01502280 | Fluorescence-guided Surgery for Low- and High-grade Gliomas(BALANCE) | completed | Phase 3 | 127 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT02879682 | nTMS for Motor Mapping of Rolandic Lesions(Motorstim) | completed | Phase 2 / Phase 3 | 330 | Technical University of MunichOTHER | 3 | Jun 1, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT03534050 | Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy | unknown | Phase 2 / Phase 3 | 80 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03762343 | Ultrasound-guided Greater Occipital Nerve Block in Children Undergoing Posterior Fossa Craniotomy | completed | Phase 3 | 40 | Kasr El Aini HospitalOTHER | 1 | Aug 15, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 18, 2026source: clinicaltrials